Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034)

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

02 Sep, 2025, 21:31 GMT

Share this article

Share toX

Share this article

Share toX

The Clostridioides difficile infection market is predicted to boost mainly owing to an increased aging population, increased focus on R&D on antimicrobial resistance solutions, ongoing public health initiatives, and approval/adoption of next-generation therapies that address both recurrence and antimicrobial resistance. Additionally, CDI prophylactic vaccines are expected to contribute to the market growth for CDI over the forecast period (2025–2034).

LAS VEGAS, Sept. 2, 2025 /PRNewswire/ -- DelveInsight's Clostridioides difficile Infection Market Insights report includes a comprehensive understanding of current treatment practices, Clostridioides difficile infection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Clostridioides difficile Infection Market Summary

  • According to DelveInsight's analysis, the market size for Clostridioides difficile infection was found to be around USD 500 million in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] in 2024. The current Clostridioides difficile infection market is dominated by DIFICID (fidaxomicin), the first antibacterial antibiotic to be approved in the US in over 25 years (May 27, 2011).
  • The burden of Clostridioides difficile Infection is highest in the US, followed by EU4 and the UK, with the US representing the largest patient pool for Clostridioides difficile Infection. Incidence trends and disease patterns vary between countries due to differences in diagnostic practices, healthcare infrastructure, and surveillance systems. The total number of incident cases of Clostridioides difficile Infection in the 7MM was around 610,800 in 2024.
  • Healthcare-associated Clostridioides difficile Infection (HA-CDI) cases have declined in regions such as the US, EU4, and Japan, driven by stronger infection control measures, reduced antibiotic misuse, and improved diagnostic practices. These efforts have also reduced the prevalence of the hypervirulent ribotype 027 strain. In contrast, the UK has seen a rise in Clostridioides difficile Infection cases, likely linked to increased overall antimicrobial use in recent years.
  • Merck's ZINPLAVA was discontinued in January 2025, despite its clinical value, particularly when used in combination with antibiotic regimens. Merck has not cited any specific reason for ZINPLAVA's withdrawal.
  • Leading Clostridioides difficile infection companies developing emerging therapies, such as Mikrobiomik, Vedanta Biosciences, Lumen Bioscience, Acurx Pharmaceuticals, Crestone, Destiny Pharma, Immuron, Sebela Pharmaceuticals, Pfizer, Idorsia, and others, are developing new Clostridioides difficile Infection treatment drugs that can be available in the Clostridioides Difficile infection market in the coming years.
  • The promising Clostridioides Difficile infection therapies in clinical trials include MBK-01, VE303, LMN-201, Ibezapolstat, CRS3123, NTCD-M3 (VP20621), PF-07831694, IDOR-1134-2831 and others.
  • In the EU, fecal microbiota transplantation (FMT) has not been approved. Mikrobiomik' MBK-01 is expected to become Europe's "first intestinal microbiota-based biologic". It is the only emerging single-dose therapeutic agent for the treatment of primary and recurrent CDI.
  • The limited availability of parenteral Clostridioides difficile Infection therapies presents a clear opportunity for innovation. Many patients are unable to receive oral treatment due to clinical constraints; however, current non-oral options remain limited to intravenous metronidazole or localized vancomycin delivery, highlighting a critical gap in accessible, effective alternatives.
  • With their investigational vaccines, companies such as Pfizer (PF-07831694) and Idorsia (IDOR-1134-2831) are planning to tap the prevention of Clostridioides difficile Infection market.

Discover the CDI new treatment @ New Treatments for CDI

Key Factors Driving the Growth of the Clostridioides difficile Infection (CDI) Market 

Aging CDI population and at-risk groups

Advanced age, frequent hospital exposure, comorbidities, and immunosuppression are major risk factors for CDI. Global population aging and increased hospital/long-term care use concentrate vulnerable patients, thereby enlarging the addressable CDI market. According to DelveInsight analysis, in 2024, the incidence of CDI in the US was estimated at approximately 184,000 cases in individuals aged 65 years and older.

Need for next-generation CDI therapies and vaccines

With vancomycin's efficacy declining due to the rise of antimicrobial resistance, there is a clear need for next-generation treatments. While current therapies reduce recurrence, a significant opportunity exists to expand preventive strategies, including CDI vaccines, which hold considerable clinical and economic promise despite the limited number of candidates currently in development.

Ibezapolstat: A dual advantage in CDI treatment

Ibezapolstat demonstrates a dual benefit of clinical efficacy comparable to that of standard-of-care antibiotics, while preserving and positively modulating the gut microbiome — an increasingly significant advantage as microbiome restoration therapies, such as fecal microbiota transplantation and live biotherapeutics, gain traction in managing recurrent CDI by addressing underlying dysbiosis.

Expanding CDI pipeline

The CDI pipeline includes several drugs in mid- to late-stage development that are anticipated to gain approval soon. The evolving landscape features a broad spectrum of therapeutic options, such as MBK-01 (Mikrobiomik), VE303 (Vedanta Biosciences), and LMN-201 (Lumen Bioscience), among others. The anticipated launch of these therapies is likely to drive further positive momentum in the market.

Clostridioides difficile Infection Market Analysis

Clostridioides difficile infection continues to pose a major public health burden globally, particularly within healthcare environments. Although diagnostic and treatment approaches have progressed, the CDI market still faces substantial therapeutic challenges, most notably the high recurrence rate, which impacts 25–45% of patients depending on disease severity and recurrence history. Over the past decade, treatment options have evolved; once dominated by metronidazole and vancomycin, the standard of care has shifted toward fidaxomicin (approved in 2011) due to its targeted, narrow-spectrum activity.

Key therapies currently shaping the CDI treatment space include DIFICID, VOWST, and REBYOTA. In a notable development, Merck withdrew ZINPLAVA from the market in January 2025, signaling a shift in the treatment landscape. ZINPLAVA, approved by the FDA in October 2016, was introduced as a monoclonal antibody targeting toxin B, designed to prevent recurrent Clostridium difficile infection (rCDI) in high-risk adults. DIFICID (fidaxomicin), initially approved in 2011 for adults with CDI, extended its label in 2020 to include children as young as 6 months, solidifying its role as a frontline treatment.

Fecal microbiota transplantation (FMT), previously limited to investigational use, has since become a regulated therapeutic approach. While off-label use in the US began around 2008 to prevent recurrent CDI, challenges such as variability in spore composition due to donor differences remain. Nevertheless, leading guidelines in the US and Europe recommend FMT after the second recurrence. Recently, two FDA-approved FMT-based treatments, VOWST (by Seres Therapeutics and Nestlé) and REBYOTA (by Ferring Pharmaceuticals), have emerged as approved preventive therapies for rCDI.

REBYOTA, the first FDA-approved FMT product (approved in 2022), is rectally administered and, despite its less convenient route, is widely used in institutions for its affordability, single-dose format, and first-mover advantage. In contrast, VOWST is an oral, microbiota-based live biotherapeutic product (LBP) that has gained substantial market traction due to its convenient administration and proven efficacy.

To know more about FDA-approved drugs for CDI, visit @ Approved CDI Treatment

Clostridioides difficile Infection Competitive Landscape

The CDI pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The CDI drugs landscape holds a diverse range of therapeutic alternatives for treatment, including MBK-01 (Mikrobiomik), VE303 (Vedanta Biosciences), LMN-201 (Lumen Bioscience), Ibezapolstat (Acurx Pharmaceuticals), and others.

MBK-01 is an investigational therapy derived from faecal microbiota transplantation, offering a promising alternative to current treatments for Clostridioides difficile infection. It is the first microbiota-based biologic approved in the EU, developed as Full-spectrum Purified Intestinal Microbiota (FSPIM) and formulated into lyophilized oral capsules.

In February 2025, Mikrobiomik announced a key milestone with the European Medicines Agency (EMA) approving its Paediatric Investigation Plan (PIP) for MBK-01, targeting CDI treatment in children. Earlier, In January 2025, the company received top recognition at the Quality Innovation Awards 2024, winning both the "Best Innovation in the Healthcare Sector" and the overall "Innovation of Innovations" award.

According to Mikrobiomik's development timeline, submission of the Clinical Trial Dossier (CTD) and Marketing Authorisation Application (MAA) for MBK-01 is planned for 2026, with a commercial launch expected in 2027.

VE303, developed by Vedanta Biosciences, is a potential first-in-class live biotherapeutic for the prevention of recurrent CDI. It is an orally delivered, defined bacterial consortium composed of eight precisely selected strains. Unlike donor-derived products, VE303 is produced from pure clonal bacterial cell banks, resulting in a consistent powdered formulation that eliminates variability associated with donor fecal material.

The ongoing Phase III RESTORATiVE303 trial is assessing VE303's safety and efficacy in rCDI patients and is intended to support a future Biologics License Application (BLA) submission to the US FDA. VE303 was granted Orphan Drug Designation (ODD) in 2017 and Fast Track Designation (FTD) in 2023 by the FDA for the prevention of rCDI.

Ibezapolstat, a novel oral antibiotic under development by Acurx Pharmaceuticals, belongs to a new class of DNA polymerase IIIC inhibitors. It targets C. difficile specifically, while preserving beneficial gut bacteria, such as other Firmicutes and Actinobacteria, to help maintain microbiome balance.

In June 2025, Acurx published results from its Phase IIb clinical trial in Lancet Microbe, highlighting the efficacy, safety, pharmacokinetics, and microbiome outcomes of ibezapolstat versus vancomycin in adults with CDI.

Additionally, in January 2025, Acurx received favorable regulatory feedback from the EMA for its Phase III clinical program for ibezapolstat. The agency also confirmed the regulatory path toward a future MAA submission upon successful trial completion.

The anticipated launch of these emerging therapies are poised to transform the Clostridioides difficile infection market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Clostridioides difficile infection market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about Clostridioides difficile infection drugs in development @ Clostridioides difficile Infection Clinical Trials

Recent Developments in the Clostridioides difficile Infection Market

  • In June 2025, a significant advancement in the development of Idorsia's first bacterial vaccine for Clostridioides difficile Infection, which is based on the company's synthetic glycan chemistry platform, was reported. Initial data showed that their C. dfficile vaccine is well-tolerated and showed immunogenicity in a Phase I study.
  • In April 2025, Lumen Bioscience announced the achievement of a 100% clinical cure rate for CDI in the sentinel cohort (Part A) of its REPREVE clinical trial, with LMN-201.
  • In February 2025, Mikrobiomik announced it had reached a new milestone upon receiving the approval of the Paediatric Investigation Plan (PIP) from the EMA for the treatment of CDI in paediatric patients.
  • In January 2025, Merck officially discontinued ZINPLAVA injection, used to prevent the rCDI.
  • In January 2025, Vedanta Biosciences announced the publication of additional results from the Phase II CONSORTIUM study for its lead candidate, VE303, which is being evaluated for the prevention of rCDI.

Clostridioides difficile Infection Overview

Clostridioides difficile infection is a severe gastrointestinal disease caused by toxin-producing C. difficile bacteria, commonly associated with the use of antibiotics and healthcare environments. It manifests as either healthcare-associated (HA-CDI) or community-associated (CA-CDI) infections and can range in severity from mild diarrhea to severe, potentially fatal colitis. CDI poses a major public health challenge due to its high recurrence rate and the significant strain it places on healthcare systems.

Diagnostic approaches have evolved. The widespread adoption of Nucleic Acid Amplification Tests (NAATs) initially led to a rise in reported cases. However, to curb overdiagnosis, there is now a greater focus on diagnostic stewardship, with a renewed emphasis on confirming positive NAAT results using toxin Enzyme Immunoassay (EIA).

Clostridioides difficile Infection Epidemiology Segmentation

The Clostridioides difficile infection epidemiology section provides insights into the historical and current Clostridioides difficile infection patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The Clostridioides difficile infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

  • Total Incident Cases of CDI by Type (HA-CDI and CA-CDI)
  • Gender-specific Incident Cases of CDI
  • Severity-specific Incident Cases of CDI
  • Age-specific Incident Cases of CDI
  • CDI Treated, Recurrent (mortality-adjusted)

Clostridioides difficile Infection Market Report Metrics

Details

Study Period

2020–2034

Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Clostridioides difficile Infection Market CAGR in the 7MM

13.5 %

Clostridioides difficile Infection Market Size in the 7MM (2024)

USD 500 million

Key Clostridioides difficile Infection Companies

Mikrobiomik, Vedanta Biosciences, Lumen Bioscience, Acurx Pharmaceuticals, Crestone, Destiny Pharma, Sebela Pharmaceuticals, Pfizer, Merck & Co., Tillotts Pharma, Astellas Pharma, Seres Therapeutics, Nestlé Health Science, Idorsia, Ferring Pharmaceuticals, Exeliom Biosciences, AstraZeneca, NuBiyota, Micropharm and others

Key Clostridioides difficile Infection Therapies

MBK-01, VE303, LMN-201, Ibezapolstat, CRS3123, NTCD-M3 (VP20621), PF-07831694, DIFICID/DIFICLIR/DAFCLIR, VOWST, REBYOTA, IDOR-1134-283, and others

Scope of the Clostridioides difficile Infection Market Report

  • Therapeutic Assessment: Clostridioides difficile Infection current marketed and emerging therapies
  • Clostridioides difficile Infection Market Dynamics: Key Market Forecast Assumptions of Emerging Clostridioides difficile Infection Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Clostridioides difficile Infection Market Access and Reimbursement

Download the report to understand which factors are driving Clostridioides difficile infection market trends @ Clostridioides difficile Infection Market Forecast

 Table of Contents

1

Clostridioides difficile Infection Market Key Insights

2

Clostridioides difficile Infection Market Report Introduction

3

Executive Summary

4

Key Events

5

Clostridioides difficile Infection Epidemiology and Market Forecast Methodology

6

CDI Market Overview at a Glance

6.1

Clinical Landscape Analysis (By Phase, RoA, and Molecule Type)

6.2

Market Share (%) Distribution of CDI by Class in 2024

6.3

Market Share (%) Distribution of CDI by Class in 2034

7

Disease Background and Overview of CDI

7.1

Introduction to CDI

7.2

Symptoms Associated With CDI

7.3

Clostridioides difficile Infection Causes

7.4

Clostridioides difficile Infection Risk Factors

7.5

Pathophysiology of CDI

7.6

Clinical Manifestations

7.7

Infection Prevention and Control

7.8

Clostridioides difficile Infection Diagnosis

7.9

Clostridioides difficile Infection Treatment

7.10

Diagnosis and Treatment Guidelines

8

Clostridioides difficile Infection Epidemiology and Patient Population

8.1

Key Findings

8.2

Assumptions and Rationale: The 7MM

8.3

Total Population at Risk of Developing CDI in the 7MM

8.4

Total Incident Cases of CDI in the 7MM

8.5

The United States

8.5.1

Incident Cases of CDI in the US by Type (HA-CDI and CA-CDI)

8.5.2

Gender-specific Incident Cases of CDI in the US

8.5.3

Severity-specific Incident Cases of CDI in the US

8.5.4

Age-specific Incident Cases of CDI in the US

8.5.5

CDI Treated, Recurrent, and Mortality Patient Pool in the US

8.6

EU4 and the UK

8.7

Japan

9

Patient Journey of CDI

10

Marketed Clostridioides difficile Infection Therapies

10.1

Key Cross of Marketed Therapies

10.2

DIFICID/DIFICLIR/DAFCLIR (fidaxomicin): Merck & Co./Tillotts Pharma/Astellas Pharma

10.2.1

Product Description

10.2.2

Regulatory Milestones

10.2.3

Other Developmental Activities

10.2.4

Summary of Pivotaltrial

10.2.5

Analyst Views

10.3

VOWST: Seres Therapeutics/Nestlé Health Science

10.4

REBYOTA: Ferring Pharmaceuticals

11

Emerging Clostridioides difficile Infection Drugs

11.1

Key Cross Competition

11.2

MBK-01: Mikrobiomik

11.2.1

Product Description

11.2.2

Other Development Activities

11.2.3

Clinical Development

11.2.3.1

Clinical Trial Information

11.2.4

Safety and Efficacy

11.2.5

Analyst Views

11.3

VE303: Vedanta Biosciences

11.4

LMN-201: Lumen Bioscience

11.5

Ibezapolstat: Acurx Pharmaceuticals

11.6

CRS3123: Crestone

11.7

NTCD-M3 (VP20621): Destiny Pharma/Sebela Pharmaceuticals

11.8

PF-07831694: Pfizer

12

CDI Market: 7MM Analysis

12.1

Key Findings

12.2

Clostridioides difficile Infection Market Outlook

12.3

Key Clostridioides difficile Infection Market Forecast Assumptions

12.4

Conjoint Analysis

12.5

Total Market Size of CDI in the 7MM

12.6

Market Size of CDI by Therapies in 7MM

12.7

United States Clostridioides difficile Infection Market Size

12.7.1

Total Market Size of CDI in the US

12.7.2

Market Size of CDI by Therapies in the US

12.8

EU4 and UK Clostridioides difficile Infection Market Size

12.9

Japan Clostridioides difficile Infection Market Size

13

Clostridioides difficile Infection Market Unmet Needs

14

Clostridioides difficile Infection Market SWOT Analysis

15

KOL Views on Clostridioides difficile Infection 

16

Clostridioides difficile Infection Market Access and Reimbursement

16.1

The United States

16.2

EU4 and the UK

16.3

Japan

16.4

Market Access and Reimbursement of CDI Therapies

17

Bibliography

18

Clostridioides difficile Infection Market Report Methodology

Related Reports

Clostridium difficile Infection Clinical Trial Analysis

Clostridium difficile Infection Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Clostridium difficile infection companies, including Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Lumen Bioscience, ImmuniMed, among others.

Helicobacter pylori Infection Market

Helicobacter pylori Infection Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Helicobacter pylori infection companies, including Eisai Co, MerLion Pharmaceuticals, Bayer, RaQualia Pharma, HKinno.N, SCG Cell Therapy, Recce Pharmaceuticals, Infan Industria Quimica Farmaceutica Nacional, among others.

Bacteremia Market

Bacteremia Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bacteremia companies, including Merck & Co., Ronak Daru Co., Bayer AG, Pfizer, Baxter, ANI Pharmaceuticals, Inc., Theravance Biopharma, Novartis AG, Fresenius SE & Co. KGaA, Mylan N.V., Sun Pharmaceutical Industries Ltd., among others.

Staphylococcus aureus Bacteremia Market

Staphylococcus aureus Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Staphylococcus aureus companies, including ContraFect, XBiotech, Genentech, Durata Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

TLR7/8 Agonists Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight

TLR7/8 Agonists Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight

DelveInsight's TLR 7/8 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight

Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight

DelveInsight's Pharmaceutical Contract Manufacturing Market Insights report provides the current and forecast market analysis, individual leading...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.